TICKERNERD
Menu
MEDPMEDPHealthcare · Diagnostics & Research

MEDP Stock Forecast: Medpace Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$579
−0.59% on the day

The 13 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $605 — +4.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$16.1B
Ticker Nerd rank
99 / 100
Median analyst target
$605
Analysts covering
13
Total return, dividends reinvested
1W
−2.1%
1M
+7.9%
YTD
+3.0%
1Y
+26.1%
From 52W high
−6.8%
From 52W low
+47.0%
$393
$621
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MEDP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Revisions
95
Momentum
88
Issuance
87
Volatility
76
Growth
74
Accruals
71
Value
70
Size
12

Quality (98): The business earns solid, repeatable profits on what it owns.

Value (70): The shares cost a lot relative to the profits and assets behind them.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MEDP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700Oct 25Jan 26Apr 26Jul 26MEDPHigh $692Median $605Low $370

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
2 Buy10 Hold1 Sell
Low $370Median $605High $692

The green dot is the last close — the median target sits +4.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 July 2026BairdMaintainsNeutral$547 → $624
24 July 2026BMO CapitalMaintainsMarket Perform$400 → $600
24 July 2026MizuhoMaintainsOutperform$586 → $665
24 July 2026RBC CapitalMaintainsOutperform$484 → $692
24 July 2026TD CowenMaintainsHold$419 → $492
24 July 2026Truist SecuritiesMaintainsHold$462 → $609
13 July 2026MizuhoMaintainsOutperform—
13 July 2026MizuhoMaintainsOutperform$495 → $586
8 July 2026BairdDowngradeNeutral—
8 July 2026BairdDowngradeNeutral$477 → $547
7 July 2026JefferiesDowngradeHold—
7 July 2026JefferiesDowngradeHold$490 → $515
24 Apr 2026BairdMaintainsOutperform—
24 Apr 2026BarclaysMaintainsEqual-Weight—
24 Apr 2026BMO CapitalMaintainsMarket Perform—
24 Apr 2026RBC CapitalMaintainsOutperform—
6 Mar 2026BarclaysUpgradeEqual-Weight—
3 Mar 2026RBC CapitalInitiatesOutperform—
18 Feb 2026TD CowenUpgradeHold—
13 Feb 2026JefferiesUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MEDP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MEDP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.5%
Analysts raising
8
Analysts cutting
0
Fundamentals

Medpace Holdings, Inc. (MEDP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
34.0×

Cheaper than 24% of US stocks

Price / sales
5.8×

Cheaper than 23% of US stocks

Price / book
37.2×

Cheaper than 3% of US stocks

EV / EBITDA
25.8×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
17.2%

Higher than 66% of US stocks

Earnings growth (YoY)
34.5%

Higher than 69% of US stocks

Gross margin
28.5%

Higher than 33% of US stocks

Operating margin
20.8%

Higher than 80% of US stocks

Net margin
17.7%

Higher than 81% of US stocks

Returns & dividend
Return on equity
162.2%

Higher than 98% of US stocks

Return on assets
20.1%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MEDP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
MEDPMedpace Holdings, Inc.$16.1B
99
CRLCharles River Laboratories International, Inc.$13.8B
84
GHGuardant Health, Inc.$20.3B
46
RVTYRevvity, Inc.$13.0B
93
ICLRIcon PLC$12.5B
67
DGXQuest Diagnostics, Inc.$26.1B
94
LHLabcorp Holdings, Inc.$26.4B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MEDP news & analysis

CON or MEDP: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 10 Aug 2026neutral

A Zacks Investment Research piece compares Concentra Group (CON) and Medpace (MEDP) in the Medical Services sector, examining which presents a better value opportunity for investors right now. No conclusion is provided in the excerpt.

Why it matters — The article directly evaluates Medpace's value standing relative to a sector peer, which is relevant for investors assessing MEDP's attractiveness.

Here's Why Medpace (MEDP) is a Strong Growth Stock

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research highlights Medpace (MEDP) as a strong growth stock, noting that its Zacks Style Scores system helps investors identify top-rated stocks based on investing style.

Why it matters — MEDP watchers would care because the piece affirms the company's strong growth-stock positioning according to Zacks' style-based ranking methodology.

Medpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?

Zacks Investment Research · 7 Aug 2026positive

Medpace Holdings (MEDP) reached a significant support level, and its 50-day simple moving average broke above its 200-day moving average, a technical pattern known as a "golden cross." Zacks notes this may make MEDP a good pick from a technical perspective.

Why it matters — A golden cross for MEDP's moving averages is a technical signal that watchers of the stock often track as an indicator of a possible positive shift in price momentum.

Is MEDP Worth Buying as Growth Collides With a Premium Valuation?

Zacks Investment Research · 6 Aug 2026neutral

Zacks Investment Research reports that Medpace combines double-digit growth, record awards, and a strong balance sheet with a rich valuation. The article raises the question of whether the stock's premium already prices in its outlook. Both growth positives and valuation concerns are presented without a definitive verdict.

Why it matters — MEDP watchers would care because the report highlights the tension between Medpace's strong operational fundamentals and its premium share price, a key consideration in assessing current positioning.

Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?

Zacks Investment Research · 5 Aug 2026positive

Medpace Holdings regained commercial momentum in the second quarter of 2026, driven by record awards and a higher book-to-bill ratio that reversed a weaker first-quarter trend.

Why it matters — The Q2 booking strength signals a potential reversal of the early-year slowdown, making near-term revenue visibility a key focus for investors tracking MEDP's growth trajectory.

FAQ

Frequently asked questions about MEDP stock

What is the MEDP stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $605, with estimates ranging from $370 to $692. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MEDP stock a buy right now?

Of the 13 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 99 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MEDP?

As at 15 Aug 2026, Medpace Holdings, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will MEDP stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +4.5% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 99 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MEDP stock forecast for 2030?

No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $692 over the next 12 months.

How has MEDP stock performed over the past year?

Medpace Holdings, Inc. returned +26.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medpace Holdings, Inc. do?

Medpace Holdings Inc. is a contract research organization that provides clinical development services for pharmaceutical, biotechnology, and medical device companies.

What is the latest news on MEDP?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "CON or MEDP: Which Is the Better Value Stock Right Now?". A Zacks Investment Research piece compares Concentra Group (CON) and Medpace (MEDP) in the Medical Services sector, examining which presents a better value opportunity for investors right now. No conclusion is provided in the excerpt.

Company

About Medpace Holdings, Inc.

Medpace Holdings Inc. is a contract research organization that provides clinical development services for pharmaceutical, biotechnology, and medical device companies. Medpace supports the drug and device trial process across all major stages, offering study design, clinical monitoring, regulatory support, data management, biostatistics, pharmacovigilance, and project management. The company also provides specialized capabilities such as bioanalytical laboratory work, imaging services, clinical pharmacology, and electrocardiography support for trials. Its integrated service model is designed to help clients coordinate complex research programs from early planning through post-marketing support. Medpace Holdings Inc. serves customers across North America, Europe, Asia, and other global markets, making it an important outsourced partner in the clinical research industry.

CEO Dr. August James Troendle M.D. · 6,500 employees · United States · https://www.medpace.com